Name: | vildagliptin |
---|---|
PubChem Compound ID: | 11077541 |
Molecular formula: | C17H25N3O2 |
Molecular weight: | 303.399 g/mol |
Name: | vildagliptin |
---|---|
Name (isomeric): | DB04876 |
Drug Type: | small molecule |
Synonyms: |
LAF237; NVP-LAF-237; NVP-LAF237; Galvus; Jalra; EQUA; LAF 237; Xiliarx
|
Brand: | Galvus |
Category: | Hypoglycemic Agents, Antidiabetic |
CAS number: | 274901-16-5 |
Indication: | Used to reduce hyperglycemia in type 2 diabetes mellitus. |
---|---|
Pharmacology: |
Vildagliptin belongs to a class of orally active antidiabetic drugs (DPP-IV inhibitors) that appear to have multiple functional benefits beyond simple blood-glucose control. One of these is a potential protective effect on pancreatic beta cells, which deteriorate in diabetes. Vildagliptin appears to be safe, very well tolerated, and efficacious. Fo...
show more » |
Mechanism of Action: | Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4). This in turn inhibits the inactivation of GLP-1 by DPP-4, allowing GLP-1 to potentiate the secretion of insulin in the beta cells. Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP and the degradation of GLP-1. |
Absorption: | Rapidly absorbed following oral administration with an oral bioavailability of greater than 90%. |
Protein binding: | 9.3% |
Half Life: | The elimination half-life is approximately 90 minutes. |
Affected organisms: | Humans and other mammals |